The University of North Carolina at Chapel Hill

Amolyt Pharma

Maine Medical Center

David Clemmons

Laura A Maile

Francis Joseph Carr

Timothy David Jones

Michael Naso

Thierry Abribat

Simon William Keen

Thomas Delale

Gang Xi

Clifford J Rosen

Stephane Milano

Michel Julien

The present technology generally relates to compounds, in particular peptides comprising the heparin-binding domain (HBD) of insulin-like growth factor binding protein-2 (IGFBP-2) for the modulation of metabolic disorders. The present technology also generally relates to uses of such compounds in methods for preventing and/or treating metabolic disorders and in compositions and formulations for such uses.

Heparin-binding domain of IGFBP-2 in the treatment of metabolic disorders

The present technology generally relates to peptides of IGFBP-2 that may be used to improve bone disorders. The present technology also generally relates to uses of such peptides in methods for preventing or treating bone disorders and to compositions for such uses.

Compounds, compositions and uses thereof for improvement of bone disorders

The present invention provides &#x3b1;V&#x3b2;3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.

Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I

The present invention provides an antibody or antigen-binding fragment thereof that binds &#x3b1;&#x3b2;integrin, as well as methods of use in the treatment of diseases and disorders.

Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)

Provided herein is technology relating to antagonists that inhibit, reduce, or minimize the interaction of integrin associated protein (IAP) with Src homology 2 (SH2) domain-containing protein tyrosine phosphatase substrate 1 (SHPS1) and particularly, but not exclusively, to compositions comprising such antagonists and methods of treatment comprising administering such antagonists.

Antagonists of IAP-SHPS1 interaction

The present invention provides peptides and methods of their use in treating bone disorders and bone-related conditions and in treating obesity.

Compounds and methods for treating bone disorders and controlling weight

A method of inhibiting cellular activation by insulin-like growth factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described.

Growing community of inventors

Chapel Hill, NC, United States of America

David Clemmons